Emergent Biosolutions Inc. (NYSE:EBS) Given Consensus Rating of “Hold” by Brokerages

Shares of Emergent Biosolutions Inc. (NYSE:EBS) have been assigned an average recommendation of “Hold” from the five analysts that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $12.00.

A number of brokerages have commented on EBS. Wall Street Zen downgraded shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Benchmark reissued a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. HC Wainwright dropped their price objective on shares of Emergent Biosolutions from $15.00 to $12.00 and set a “buy” rating on the stock in a research report on Monday, March 9th. Weiss Ratings downgraded shares of Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. Finally, UBS Group reissued a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd.

Insider Activity at Emergent Biosolutions

In related news, Director Keith Katkin sold 15,481 shares of Emergent Biosolutions stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $8.28, for a total transaction of $128,182.68. Following the sale, the director directly owned 96,294 shares in the company, valued at $797,314.32. This trade represents a 13.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn C. Zoon sold 17,202 shares of Emergent Biosolutions stock in a transaction on Friday, May 1st. The stock was sold at an average price of $8.40, for a total transaction of $144,496.80. Following the sale, the director owned 79,941 shares in the company, valued at $671,504.40. This represents a 17.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 61,925 shares of company stock valued at $518,312 over the last quarter. 6.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Emergent Biosolutions

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Torren Management LLC acquired a new stake in Emergent Biosolutions during the 4th quarter worth $37,000. CANADA LIFE ASSURANCE Co acquired a new stake in Emergent Biosolutions during the 4th quarter worth $45,000. Legal & General Group Plc acquired a new stake in Emergent Biosolutions during the 2nd quarter worth $31,000. Farther Finance Advisors LLC raised its stake in Emergent Biosolutions by 361.3% during the 4th quarter. Farther Finance Advisors LLC now owns 6,163 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 4,827 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Emergent Biosolutions during the 2nd quarter worth $53,000. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Emergent Biosolutions Trading Up 5.8%

Shares of NYSE:EBS opened at $8.45 on Friday. Emergent Biosolutions has a 52 week low of $5.61 and a 52 week high of $14.06. The company’s 50 day moving average is $8.37 and its two-hundred day moving average is $9.76. The company has a current ratio of 4.29, a quick ratio of 2.08 and a debt-to-equity ratio of 1.10. The company has a market cap of $435.81 million, a PE ratio of -30.16 and a beta of 2.33.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $0.21 EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.46. Emergent Biosolutions had a negative net margin of 1.27% and a positive return on equity of 10.76%. The company had revenue of $156.10 million for the quarter, compared to the consensus estimate of $145.00 million.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.